On August 5, AstraZeneca PLC rose 4.97% in regular trading, trading at 162.73 USD/share, with turnover of $351 million. The stock is recovering from a sharp selloff earlier this week triggered by merger speculation.

On the news front, multiple senior sources close to the matter explicitly confirmed that AstraZeneca and Bristol Myers Squibb have never engaged in any merger discussions. The denial effectively quashed earlier reports from August 3 suggesting the two companies were exploring a potential $400 billion combination that would have created one of the world's largest pharmaceutical companies. AstraZeneca had previously fallen over 9% on the unconfirmed merger speculation, with analysts from BMO Capital noting that neither company possessed sufficient financial capacity to fund such a transaction — AstraZeneca could raise approximately $37 billion, far below the $400 billion required.

Additionally, CSPC Pharmaceutical Group announced it signed a joint venture contract with AstraZeneca and received a $10 million milestone payment under a strategic R&D collaboration agreement, signaling positive business expansion momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)